2016
DOI: 10.1155/2016/1379274
|View full text |Cite
|
Sign up to set email alerts
|

Incretin-Based Therapy for Prevention of Diabetic Vascular Complications

Abstract: Diabetic vascular complications are the most common cause of mortality and morbidity worldwide, with numbers of affected individuals steadily increasing. Diabetic vascular complications can be divided into two categories: macrovascular andmicrovascular complications. Macrovascular complications include coronary artery diseaseand cerebrovascular disease, while microvascular complications include retinopathy and chronic kidney disease. These complications result from metabolic abnormalities, including hyperglyce… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
27
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 31 publications
(27 citation statements)
references
References 97 publications
0
27
0
Order By: Relevance
“…Diabetic vascular complications are the most common cause of mortality and morbidity worldwide, with numbers of affected individuals steadily increasing [2]. Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and remains a major cause of preventable blindness [3].…”
Section: Introductionmentioning
confidence: 99%
“…Diabetic vascular complications are the most common cause of mortality and morbidity worldwide, with numbers of affected individuals steadily increasing [2]. Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and remains a major cause of preventable blindness [3].…”
Section: Introductionmentioning
confidence: 99%
“…Incretin-based therapy seems very promising for the prevention of diabetic vascular complications (Mima 2016). The potential for GLP-1RAs to enhance vascular function has been demonstrated in several studies (Nystrom et al 2004, Smits et al 2015, Sufiun et al 2015Zhou et al 2015.…”
Section: Glp-1ras and Blood Flow To Bonementioning
confidence: 99%
“…It is likely that GLP-1 agonists also exert a neuroprotective effect by reducing vascular risk factors. Incretin therapy has been shown to improve micro and macro-vascular complications of diabetes by reducing cerebral ischaemia [62]. In addition to being effective in PD animal models, treatments with GLP-1 analogues have also resulted in improvements in memory impairment by preventing synapse loss in AD animal models [63,64], with Liraglutide being shown to have reduced the soluble Aβ oligomer [63].…”
Section: The Role Of Gip Glp-1 and Dpp4mentioning
confidence: 99%